Prabir Kumar Gharai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Prabir Kumar Gharai has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Surajit Ghosh
Smart Healthcare Interdisciplinary Research Division Indian Institute of Technology Jodhpur, Karwar Rajasthan India
9 shared publications - Juhee Khan
Department of Bioscience & Bioengineering Indian Institute of Technology NH 62, Surpura Bypass Road, Karwar Jodhpur Rajasthan 342037 India
7 shared publications Shubham Garg
Department of Bioscience & Bioengineering, Indian Institute of Technology, Jodhpur, NH 65, Surpura Bypass Road, Karwar, Rajasthan 342037, India
7 shared publications- Rathnam Mallesh
Department of Bioscience & Bioengineering, Indian Institute of Technology, Jodhpur, NH 65, Surpura Bypass Road, Karwar, Rajasthan 342037, India
6 shared publications - Pratikshya Paudel
Department of Chemistry, Oklahoma State University, Stillwater, OK 74078, USA
5 shared publications Mohammad Umar Arshi
Department of Bioscience and Bioengineering, Indian Institute of Technology, Rajasthan 342037, India
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (4) , 89
From Antioxidants to Multi-Target Therapeutics: Preclinical and Emerging Evidence for Flavonoid Neuroprotection in Neurodegenerative Diseases
Flavonoids are plant-derived polyphenols found in fruits, vegetables, tea and other dietary sources. Global dementia prevalence is projected to rise sharply, and current disease-modifying therapies remain limited in efficacy. This gap has contributed to growing interest in dietary flavonoids as multi-target neuroprotective agents. This review draws together mechanistic, preclinical, and early clinical evidence for six flavonoid subclasses (flavanones, flavonols, flavones, flavanols, anthocyanins, isoflavones) across five neuroprotective mechanisms: antioxidant defense, suppression of neuroinflammation, inhibition of pathogenic protein aggregation, promotion of neurogenesis and synaptic density, and preservation of blood–brain barrier integrity. We also summarize proposed structure–activity relationships linking substitution patterns (catechol groups, hydroxylation, glycosylation) to these mechanisms. Most of this evidence comes from in vitro and rodent models. Longitudinal cohorts do link dietary intake to slower cognitive decline, but clinical trials remain few, early-phase, and inconsistent; some report negligible change on clinical metrics such as the UPDRS scale. Certain flavonoid metabolites are detected in rodent brain tissue after oral dosing, though whether humans achieve pharmacologically meaningful brain exposure at dietary or supplemental doses is still unresolved. Translation faces substantial barriers: limited oral bioavailability, extensive first-pass metabolism, inconsistent blood–brain barrier penetration, and wide inter-individual variability in metabolism, gut microbiome composition, and trial design. We close by outlining strategies, including nanoparticle delivery, prodrug design, and precision nutrition approaches, that could move flavonoids closer to clinical relevance.
- 1 October 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (4) , 89
Open AccessFrom Antioxidants to Multi-Target Therapeutics: Preclinical and Emerging Evidence for Flavonoid Neuroprotection in Neurodegenerative Diseases
Flavonoids are plant-derived polyphenols found in fruits, vegetables, tea and other dietary sources. Global dementia prevalence is projected to rise sharply, and current disease-modifying therapies remain limited in efficacy. This gap has contributed to growing interest in dietary flavonoids as multi-target neuroprotective agents. This review draws together mechanistic, preclinical, and early clinical evidence for six flavonoid subclasses (flavanones, flavonols, flavones, flavanols, anthocyanins, isoflavones) across five neuroprotective mechanisms: antioxidant defense, suppression of neuroinflammation, inhibition of pathogenic protein aggregation, promotion of neurogenesis and synaptic density, and preservation of blood–brain barrier integrity. We also summarize proposed structure–activity relationships linking substitution patterns (catechol groups, hydroxylation, glycosylation) to these mechanisms. Most of this evidence comes from in vitro and rodent models. Longitudinal cohorts do link dietary intake to slower cognitive decline, but clinical trials remain few, early-phase, and inconsistent; some report negligible change on clinical metrics such as the UPDRS scale. Certain flavonoid metabolites are detected in rodent brain tissue after oral dosing, though whether humans achieve pharmacologically meaningful brain exposure at dietary or supplemental doses is still unresolved. Translation faces substantial barriers: limited oral bioavailability, extensive first-pass metabolism, inconsistent blood–brain barrier penetration, and wide inter-individual variability in metabolism, gut microbiome composition, and trial design. We close by outlining strategies, including nanoparticle delivery, prodrug design, and precision nutrition approaches, that could move flavonoids closer to clinical relevance.
- Open Access
- 10 July 2026
- Published by MDPI AG in Preprints.org
From Antioxidants to Multi-Target Therapeutics: The Emerging Role of Flavonoids in Neurodegenerative Diseases
Flavonoids represent a varied collection of polyphenolic compounds derived from plants, present in numerous food sources, including fruits, vegetables, tea, coffee, honey, and various medicinal plants. Historically, these compounds have garnered attention regarding their potential effects on brain health, a focus that has grown particularly urgent due to the escalating global prevalence of neurodegenerative disorders. Diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and other forms of cognitive decline associated with ageing now impact millions, highlighting the pressing demand for therapeutic approaches that are both safe and biologically relevant. A substantial body of empirical research indicates that flavonoids may interact with multiple pathways that influence neuronal sensitivity. Various subclasses of flavonoids appear to modulate oxidative homeostasis, inflammatory signaling, mitochondrial function, and synaptic communication. In a range of in vitro and in vivo investigations, these compounds have demonstrated the capacity to neutralize reactive oxygen species, regulate apoptotic and inflammatory pathways, and facilitate processes integral to neurogenesis and synaptic plasticity. Certain metabolites possess the ability to traverse the blood–brain barrier, suggesting a more profound interaction with neural tissue than initially believed. This chapter synthesizes preclinical and clinical data on prominent flavonoid subclasses, including flavanones, flavanols, flavones, flavonols, anthocyanins, and isoflavones, and explores how their structural characteristics may correlate with neuroprotective effects. The discussion extends to the principal barriers that hinder the transition of these compounds into clinical applications, including limited bioavailability, metabolic differences among individuals, dose-dependent effects, and the challenge of translating experimental outcomes to human contexts. Potential strategies aimed at enhancing their therapeutic profiles are also considered.
- 10 July 2026
- Published by MDPI AG in Preprints.org
Open AccessFrom Antioxidants to Multi-Target Therapeutics: The Emerging Role of Flavonoids in Neurodegenerative Diseases
Flavonoids represent a varied collection of polyphenolic compounds derived from plants, present in numerous food sources, including fruits, vegetables, tea, coffee, honey, and various medicinal plants. Historically, these compounds have garnered attention regarding their potential effects on brain health, a focus that has grown particularly urgent due to the escalating global prevalence of neurodegenerative disorders. Diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and other forms of cognitive decline associated with ageing now impact millions, highlighting the pressing demand for therapeutic approaches that are both safe and biologically relevant. A substantial body of empirical research indicates that flavonoids may interact with multiple pathways that influence neuronal sensitivity. Various subclasses of flavonoids appear to modulate oxidative homeostasis, inflammatory signaling, mitochondrial function, and synaptic communication. In a range of in vitro and in vivo investigations, these compounds have demonstrated the capacity to neutralize reactive oxygen species, regulate apoptotic and inflammatory pathways, and facilitate processes integral to neurogenesis and synaptic plasticity. Certain metabolites possess the ability to traverse the blood–brain barrier, suggesting a more profound interaction with neural tissue than initially believed. This chapter synthesizes preclinical and clinical data on prominent flavonoid subclasses, including flavanones, flavanols, flavones, flavonols, anthocyanins, and isoflavones, and explores how their structural characteristics may correlate with neuroprotective effects. The discussion extends to the principal barriers that hinder the transition of these compounds into clinical applications, including limited bioavailability, metabolic differences among individuals, dose-dependent effects, and the challenge of translating experimental outcomes to human contexts. Potential strategies aimed at enhancing their therapeutic profiles are also considered.
- Open Access
- 8 January 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (1) , 6
Crocin Modified Drugs for Neuronal Trans-Differentiation: A Future Regenerative Approach
Neurodegeneration—driven by oxidative stress, chronic inflammation, and protein aggregation—underlies disorders such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and stroke. Current pharmacological treatments are largely symptomatic and do not restore lost neural circuitry, motivating regenerative approaches. Mesenchymal stem cells (MSCs) provide neurotrophic and immunomodulatory benefits and can support synaptic repair, yet robust conversion into mature, electrophysiologically functional neurons remain challenging and often depends on complex inducer cocktails with translational limitations. Crocin, a saffron-derived carotenoid, is reported to enhance neurogenesis and neuroprotection in preclinical models through pathways including Wnt/β-catenin, Notch1, CREB/BDNF, and modulation of GSK-3β, while reducing apoptosis and inflammatory signaling. Here, we synthesize evidence supporting crocin’s neuroprotective and proneurogenic activity and propose a testable hypothesis that crocin-based or crocin-modified formulations could be evaluated as adjuncts to guide MSC neuronal lineage commitment. Importantly, direct evidence that crocin alone can drive MSC trans-differentiation into fully functional neurons is currently insufficient; future work should define functional benchmarks (electrophysiology, synaptogenesis, and phenotypic stability) and rigorously validate safety, dosing, and delivery strategies for neuroregenerative translation.
- 8 January 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (1) , 6
Open AccessCrocin Modified Drugs for Neuronal Trans-Differentiation: A Future Regenerative Approach
Neurodegeneration—driven by oxidative stress, chronic inflammation, and protein aggregation—underlies disorders such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and stroke. Current pharmacological treatments are largely symptomatic and do not restore lost neural circuitry, motivating regenerative approaches. Mesenchymal stem cells (MSCs) provide neurotrophic and immunomodulatory benefits and can support synaptic repair, yet robust conversion into mature, electrophysiologically functional neurons remain challenging and often depends on complex inducer cocktails with translational limitations. Crocin, a saffron-derived carotenoid, is reported to enhance neurogenesis and neuroprotection in preclinical models through pathways including Wnt/β-catenin, Notch1, CREB/BDNF, and modulation of GSK-3β, while reducing apoptosis and inflammatory signaling. Here, we synthesize evidence supporting crocin’s neuroprotective and proneurogenic activity and propose a testable hypothesis that crocin-based or crocin-modified formulations could be evaluated as adjuncts to guide MSC neuronal lineage commitment. Importantly, direct evidence that crocin alone can drive MSC trans-differentiation into fully functional neurons is currently insufficient; future work should define functional benchmarks (electrophysiology, synaptogenesis, and phenotypic stability) and rigorously validate safety, dosing, and delivery strategies for neuroregenerative translation.
- Open Access
- 10 December 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (12) , 5765-5769
Sequence-controlled peptoid hydrogels for neuronal trans-differentiation: a synthetic biomaterials approach in future neuroregenerative research
Transplanted stem cells, when supported by peptoid-based hydrogels, demonstrate enhanced migration to the injury site, improved survival rates, and facilitate brain repair through the formation of new connections and support for recovery.
- 10 December 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (12) , 5765-5769
Open AccessSequence-controlled peptoid hydrogels for neuronal trans-differentiation: a synthetic biomaterials approach in future neuroregenerative research
Transplanted stem cells, when supported by peptoid-based hydrogels, demonstrate enhanced migration to the injury site, improved survival rates, and facilitate brain repair through the formation of new connections and support for recovery.
- Open Access
- 15 September 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (19) , 3631-3633
Cell-Penetrating Peptoids: A Dual Functional Strategy for Upcoming Neuroregeneration Application
Effective therapies for neurological conditions are a significant challenge since limited capacity of neurons for regeneration affects neuronal recovery. Despite their ineffective in vivo direct development into neurons, human mesenchymal stem cells (hMSCs) exhibit therapeutic promise through immunological regulation, neuroprotection, and improvement of endogenous repair. A promising strategy is to convert hMSCs into functional neurons using peptoids that also possess cell-penetrating abilities. Therefore, developing cell-penetrating peptoids that combine effective cellular uptake with neural differentiation induction could significantly progress neuroscience research and neuroregenerative treatments.
- 15 September 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (19) , 3631-3633
Open AccessCell-Penetrating Peptoids: A Dual Functional Strategy for Upcoming Neuroregeneration Application
Effective therapies for neurological conditions are a significant challenge since limited capacity of neurons for regeneration affects neuronal recovery. Despite their ineffective in vivo direct development into neurons, human mesenchymal stem cells (hMSCs) exhibit therapeutic promise through immunological regulation, neuroprotection, and improvement of endogenous repair. A promising strategy is to convert hMSCs into functional neurons using peptoids that also possess cell-penetrating abilities. Therefore, developing cell-penetrating peptoids that combine effective cellular uptake with neural differentiation induction could significantly progress neuroscience research and neuroregenerative treatments.
- Open Access
- 17 July 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (15) , 2753-2755
Can Oxytocin Neuropeptide Promote Human Mesenchymal Stem Cells to Neuron Conversion?: A Novel Approach in Future Neurotherapeutic Research
Neurodegenerative diseases are characterized by progressive neuronal loss, for which human mesenchymal stem cell (hMSC)-based therapies present a promising regenerative approach. Oxytocin, a neuropeptide known for its neuroprotective and anti-inflammatory properties, has been reported to inhibit GSK-3β in certain models. Given the established role of GSK-3β inhibition in promoting neurogenesis via Wnt/β-catenin signaling, this viewpoint explores the hypothesis that oxytocin could serve as a peptide-based cue to drive neuronal differentiation of MSCs. Consequently, developing effective therapy by emulating the oxytocin sequence could substantially enhance neuroregenerative treatments in neuroregenerative research.
- 17 July 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (15) , 2753-2755
Open AccessCan Oxytocin Neuropeptide Promote Human Mesenchymal Stem Cells to Neuron Conversion?: A Novel Approach in Future Neurotherapeutic Research
Neurodegenerative diseases are characterized by progressive neuronal loss, for which human mesenchymal stem cell (hMSC)-based therapies present a promising regenerative approach. Oxytocin, a neuropeptide known for its neuroprotective and anti-inflammatory properties, has been reported to inhibit GSK-3β in certain models. Given the established role of GSK-3β inhibition in promoting neurogenesis via Wnt/β-catenin signaling, this viewpoint explores the hypothesis that oxytocin could serve as a peptide-based cue to drive neuronal differentiation of MSCs. Consequently, developing effective therapy by emulating the oxytocin sequence could substantially enhance neuroregenerative treatments in neuroregenerative research.
- Open Access
- 25 June 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (14) , 2561-2563
Dual-Function Fluorescent Probes for Neuronal Trans-Differentiation: A Promising Therapeutic Strategy in Neuroregenerative Research
Neurodegenerative diseases cause progressive neuronal loss, with current treatments offering only limited symptomatic relief. To overcome this, various strategies are being explored. One promising approach involves converting human mesenchymal stem cells (hMSCs) into functional neurons using a small molecule, alongside the use of fluorescent probes for real-time imaging. Therefore, developing a promising single compound that combines both differentiation-inducing and imaging capabilities without relying on growth factors could significantly advance neuroregenerative therapies and diagnostic strategies in neuroscience research.
- 25 June 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (14) , 2561-2563
Open AccessDual-Function Fluorescent Probes for Neuronal Trans-Differentiation: A Promising Therapeutic Strategy in Neuroregenerative Research
Neurodegenerative diseases cause progressive neuronal loss, with current treatments offering only limited symptomatic relief. To overcome this, various strategies are being explored. One promising approach involves converting human mesenchymal stem cells (hMSCs) into functional neurons using a small molecule, alongside the use of fluorescent probes for real-time imaging. Therefore, developing a promising single compound that combines both differentiation-inducing and imaging capabilities without relying on growth factors could significantly advance neuroregenerative therapies and diagnostic strategies in neuroscience research.
- 30 May 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (12) , 2224-2236
Discovery of Carbazole and Theophylline-Based Amyloid Inhibitor for the Promotion of Neuroprotection
The amyloid-beta 42 (Aβ42) peptide assembles into neurotoxic soluble oligomers and extracellular fibrillary aggregates during the progression of Alzheimer's disease (AD), which ultimately leads to amyloid plaque in the brain, causing major disruption of the neural circuit and leading to the severe loss of memory. Thus, perturbation or inhibition of this process through the development of advanced inhibitors is crucial for the treatment of AD. Here, we adopted an advanced strategy that showcases the design of a carbazole-based chemical inhibitor targeting the Aβ peptide. The new inhibitors are designed in such a way that they can bind selectively with the Aβ42 peptide and inhibit the assembly process and disease progression. Initial assessments using the thioflavin-T assay and molecular docking experiments help screen the carbazole and theophylline-based CT-01 as effective lead molecules, which bind at the N-terminal hydrophobic region of the Aβ42 peptide and inhibit the formation of soluble oligomers and extracellular fibrillary aggregates. Further, FT-IR spectroscopy, CD, TEM, dot blot, and ITC experiments suggest the inhibition potency of CT-01. Finally, the neuroprotection and apoptosis assay confirm that CT-01 reduces amyloid-mediated toxicity in neurons. The serum-stable CT-01 can also protect the NGF-deprived neurons and has the ability to cross the blood-brain barrier.
- 30 May 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (12) , 2224-2236
Discovery of Carbazole and Theophylline-Based Amyloid Inhibitor for the Promotion of Neuroprotection
The amyloid-beta 42 (Aβ42) peptide assembles into neurotoxic soluble oligomers and extracellular fibrillary aggregates during the progression of Alzheimer's disease (AD), which ultimately leads to amyloid plaque in the brain, causing major disruption of the neural circuit and leading to the severe loss of memory. Thus, perturbation or inhibition of this process through the development of advanced inhibitors is crucial for the treatment of AD. Here, we adopted an advanced strategy that showcases the design of a carbazole-based chemical inhibitor targeting the Aβ peptide. The new inhibitors are designed in such a way that they can bind selectively with the Aβ42 peptide and inhibit the assembly process and disease progression. Initial assessments using the thioflavin-T assay and molecular docking experiments help screen the carbazole and theophylline-based CT-01 as effective lead molecules, which bind at the N-terminal hydrophobic region of the Aβ42 peptide and inhibit the formation of soluble oligomers and extracellular fibrillary aggregates. Further, FT-IR spectroscopy, CD, TEM, dot blot, and ITC experiments suggest the inhibition potency of CT-01. Finally, the neuroprotection and apoptosis assay confirm that CT-01 reduces amyloid-mediated toxicity in neurons. The serum-stable CT-01 can also protect the NGF-deprived neurons and has the ability to cross the blood-brain barrier.
- Open Access
- 28 April 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (9) , 4844-4871
Discovery of powerful multifaceted antioxidant for combating oxidative stress associated with neurodegenerative disorders
- 28 April 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (9) , 4844-4871
Open AccessDiscovery of powerful multifaceted antioxidant for combating oxidative stress associated with neurodegenerative disorders
- 14 June 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (13) , 2470-2483
Power of Dopamine: Multifunctional Compound Assisted Conversion of the Most Risk Factor into Therapeutics of Alzheimer’s Disease
In Alzheimer's disease (AD), reactive oxygen species (ROS) plays a crucial role, which is produced from molecular oxygen with extracellular deposited amyloid-β (Aβ) aggregates through the reduction of a Cu2+ ion. In the presence of a small amount of redox-active Cu2+ ion, ROS is produced by the Aβ-Cu2+ complex as Aβ peptide alone is unable to generate excess ROS. Therefore, Cu2+ ion chelators are considered promising therapeutics against AD. Here, we have designed and synthesized a series of Schiff base derivatives (SB) based on 2-hydroxy aromatic aldehyde derivatives and dopamine. These SB compounds contain one copper chelating core, which captures the Cu2+ ions from the Aβ-Cu2+ complex. Thereby, it inhibits copper-induced amyloid aggregation as well as amyloid self-aggregation. It also inhibits copper-catalyzed ROS production through sequestering of Cu2+ ions. The uniqueness of our designed ligands has the dual property of dopamine, which not only acts as a ROS scavenger but also chelates the copper ion. The crystallographic analysis proves the power of the dopamine unit. Therefore, dual exploration of dopamine core can be considered as potential therapeutics for future AD treatment.
- 14 June 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (13) , 2470-2483
Power of Dopamine: Multifunctional Compound Assisted Conversion of the Most Risk Factor into Therapeutics of Alzheimer’s Disease
In Alzheimer's disease (AD), reactive oxygen species (ROS) plays a crucial role, which is produced from molecular oxygen with extracellular deposited amyloid-β (Aβ) aggregates through the reduction of a Cu2+ ion. In the presence of a small amount of redox-active Cu2+ ion, ROS is produced by the Aβ-Cu2+ complex as Aβ peptide alone is unable to generate excess ROS. Therefore, Cu2+ ion chelators are considered promising therapeutics against AD. Here, we have designed and synthesized a series of Schiff base derivatives (SB) based on 2-hydroxy aromatic aldehyde derivatives and dopamine. These SB compounds contain one copper chelating core, which captures the Cu2+ ions from the Aβ-Cu2+ complex. Thereby, it inhibits copper-induced amyloid aggregation as well as amyloid self-aggregation. It also inhibits copper-catalyzed ROS production through sequestering of Cu2+ ions. The uniqueness of our designed ligands has the dual property of dopamine, which not only acts as a ROS scavenger but also chelates the copper ion. The crystallographic analysis proves the power of the dopamine unit. Therefore, dual exploration of dopamine core can be considered as potential therapeutics for future AD treatment.